Although we are the first to demonstrate that SCARNA12 promotes CRC progression by activating the PI3K/AKT pathway, several limitations are still associated with this study: (1) the detailed mechanism of phosphorylating PI3K/AKT by which SCARNA12 needs to be explored further; (2) more clinical data and experimental studies are required to elucidate the specific function of SCARNA12 in CRC. Here, SCARNA12 is linked to colorectal carcinoma.